Follicular Lymphoma Clinical Research Trials

Birmingham : Uab Comprehensive Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Sun City : 21st Century Oncology

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Corona : Compassionate Cancer Care Medical Group, Inc.

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fountain Valley : Compassionate Cancer Care Medical Group, Inc.

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fountain Valley : Lalita Pandit, MD Inc.

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fullerton : St. Jude Heritage Medical Group

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

La Jolla : Moores Ucsd Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Los Angeles : Santa Monica Hematology/Oncology

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Los Angeles : Ucla-Division Of Hematology/Oncology

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Los Angeles : Usc - Norris Comprehensive Cancer Center And Hospital

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Palo Alto : Stanford Cancer Center

Safety and Efficacy Study of CAL-101 in Patients With Previously Treated Low-grade Lymphoma

Colorado Springs : Memorial Hospital

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Southington : Cancer Center of Central Connecticut

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boynton Beach : University Cancer Institute

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Englewood : Florida Cancer Specialist

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Fort Lauderdale : Holy Cross Hospital

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Orlando : MD Anderson Cancer Center Orlando

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

St. Petersburg : Florida Cancer Specialists

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Athens : Northeast Georgia Cancer Care

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Atlanta : Emory University Winship Cancer Institute

A Phase I/II Trial of VR-CHOP in Lymphoma Patients

Chicago : Advocate Illinois Masonic Medical Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Niles : Illinois Cancer Specialists

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Lexington : University of Kentucky

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Baton Rouge : Ochsner Clinic Baton Rouge

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Baltimore : B. Douglas Smith, M.D.

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Townson : Saint Joseph's Medical Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boston : Harvard Medical School-Mass General Hospital

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Boston : Dana-Farber Cancer Institute

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Boston : Massachusetts General Hospital

Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma

Boston : Massachusetts General Hospital

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Boston : Dana-Farber Cancer Institute

Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma

Ann Arbor : University of Michigan

Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Southfield : Newland Medical Associates

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

St. Louis : Washington University School of Medicine Siteman Cancer Center Hematology Labs

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Omaha : University of Nebraska Medical Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Hackensack : The Cancer Center at Hackensack University Medical Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Morristown : Hematology-Oncology Associates of North New Jersey

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Somerville : Somerset Hematology Oncology Associates

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

New York : Weill Cornell Medical College

Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma

New York : Memorial Sloan Kettering Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

New York : St. Luke's-Roosevelt Hospital Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

New York : Mount Sinai School of Medicine

Safety and Efficacy Study of CAL-101 in Patients With Previously Treated Low-grade Lymphoma

Fargo : Roger Maris Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Nashville : Sarah Cannon Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Dallas : Baylor Sammons Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Houston : MD Anderson Cancer Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Houston : The University Of Texas Md Anderson Cancer Center

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Lubbock : Joe Arrington Cancer Research and Treatment Center

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Richmond : Virginia Cancer Institute

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Seattle : Seattle Cancer Care Alliance

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Seattle : University Of Washington School Of Medicine

First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Charleston : Charleston Area Medical Center

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Melbourne : Peter MacCallum Cancer Centre

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)

Lille : CHU Claude Huriez

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma

Mainz : Universitätsmedizin Mainz

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Akita :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Chuo-ku :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Fukuoka :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hidaka :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Isehara :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Izumo :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kagoshima :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kanazawa :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kurashiki :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kurume :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kyoto :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Maebashi :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Matsuyama :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Nagoya :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ninomaru :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sapporo :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sendai :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Shikata-cho :

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Kuching : Investigative site

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma

Aberdeen : Aberdeen Royal Infirmary